NCT04506645View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions

Healthy

Interventions

DRUG

REGN5381

Single dose REGN5381 administered via IV infusion

OTHER

Placebo

Placebo matching single dose REGN 5381 administered via IV infusion

Trial Locations (2)

9000

Ghent University, Ghent

B-3000

Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04506645 - Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans | Biotech Hunter | Biotech Hunter